References: 1. ZOMETA® Summary of Product Characteristics. Novartis Pharma AG.
2. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated
with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907.
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
